UBS Group adjusted its rating on Jazz Pharmaceuticals PLC shares on Monday, turning bullish on the stock due to the resilience of its core operations and the commercial promise of a new cancer treatment.

The bank upgraded Jazz Pharmaceuticals from "Neutral" to "Buy" and significantly raised its price target to $307. This target suggests a potential upside of over 33% from Monday's closing price. Analyst Ashwani Verma noted in a report on Tuesday that the company's drug Ziihera, used to treat gallbladder cancer, is nearing fast-track approval ahead of a regulatory deadline on August 25. He also highlighted that the company's other business segments are performing well.

Verma stated, "We believe the stability of the sleep disorder drug franchise appears manageable in the face of pricing pressures and potential competitive entry from Orexin in the second half of 2026, and this is overshadowed by the new growth opportunity represented by Ziihera. Additionally, Modeyso, a drug for treating a type of brain cancer, is expected to generate significant sales in the next one to two years."

Since the beginning of 2026, shares of Jazz Pharmaceuticals have risen by 35%, and over the past year, they have doubled in value.